Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMEV-Applied Molecular Evolution -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (65)	1/5/2003 5:46:39 AM
From: scott_jiminez	Read Replies (1) \| Respond to of 164

If the affinity and cell-killing assays translate even partially to RA (for the TNF MAb), then AMEV may have a real winner here. I'm curious about how TNF is delivered to achieve these desired benefits; systemic elimination of TNF is not an option (except in acute and severe cases I suppose) as TNF plays a critical role during routine inflammatory events. If AME-527 could be applied safely to patients with a variety of neuropathologies involving inflammation (MS, AD, PD, etc), for example, then, theoretically, there may a be a dramatic attenuation in disease progression. The recent encouraging data showing amelioration of MS plaque progression with anti-alpha 4 Integrin (Elan/Biogen) would appear to lend support to this proposition [ Message 18391434 ]. Ron.